Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CDKN2A/p16 in ependymomas.

S Bortolotto1, L Chiadò-Piat, P Cavalla

  • 1Department of Neuroscience, University of Turin, Italy.

Journal of Neuro-Oncology
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recurrent pericarditis in children: Clinical and therapeutic differences from adults.

International journal of cardiology·2026
Same author

Depemokimab and the twice-yearly regimen: pharmacological implications and therapeutic positioning in severe eosinophilic respiratory diseases.

Frontiers in immunology·2026
Same author

A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of irritable bowel syndrome in adults.

Beneficial microbes·2025
Same author

Fetal-hope study: Home monitoring of fetal heart rate in SSA + pregnant women: Rationale and design.

European journal of obstetrics, gynecology, and reproductive biology·2024
Same author

Neurological manifestations of Kawasaki disease and multisystem inflammatory syndrome in children associated with COVID-19: A comparison of two different clinical entities.

Frontiers in pediatrics·2023
Same author

A Compartmental Model for the Iron Trafficking Across the Blood-Brain Barriers in Neurodegenerative Diseases.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2021
Same journal

Intratumoral hemorrhage in patients with brain metastasis from systemic tumors: risk factors and prognostic assessment.

Journal of neuro-oncology·2026
Same journal

Rethinking white matter-tumor interaction: a tractography based analysis of associations between fractional anisotropy and morphometry in the IFOF and arcuate fasciculus.

Journal of neuro-oncology·2026
Same journal

Divided care, diminished outcomes? The impact of care fragmentation on survival in glioblastoma.

Journal of neuro-oncology·2026
Same journal

Serum lactate dehydrogenase is associated with the presence and extent of preoperative peritumoral edema in melanoma brain metastases.

Journal of neuro-oncology·2026
Same journal

Feasibility evaluation of tumor treating fields for brainstem gliomas.

Journal of neuro-oncology·2026
Same journal

Intraoperative technological advances and new frontiers in precision glioma surgery.

Journal of neuro-oncology·2026
See all related articles

CDKN2A/p16 inactivation was studied in 16 ependymoma cases. Inactivation was rare and did not appear to drive malignant transformation in ependymomas.

Area of Science:

  • Neuro-oncology
  • Molecular Pathology
  • Cancer Genetics

Background:

  • Ependymomas are primary tumors of the central nervous system.
  • Understanding the molecular alterations in ependymomas is crucial for diagnosis and treatment.
  • CDKN2A/p16 is a tumor suppressor gene frequently altered in various cancers.

Purpose of the Study:

  • To investigate the role of CDKN2A/p16 inactivation in ependymoma pathogenesis.
  • To determine the frequency of CDKN2A/p16 inactivation in different grades of ependymoma.
  • To explore potential mechanisms of p16 inactivation in ependymomas.

Main Methods:

  • Immunohistochemistry using a p16 monoclonal antibody.
  • Homozygous deletion (HD) assay for CDKN2A.
  • 5'CpG promoter methylation assay (methylation-specific PCR).

Related Experiment Videos

Main Results:

  • Three out of 16 ependymoma cases showed p16 immuno-negativity (2 grade II, 1 grade III).
  • The single grade III ependymoma case with p16 immuno-negativity exhibited CDKN2A HD.
  • No promoter methylation was detected in immuno-negative cases lacking CDKN2A HD.

Conclusions:

  • CDKN2A/p16 inactivation appears infrequent in ependymomas.
  • Mechanisms other than homozygous deletion or promoter methylation may cause p16 inactivation.
  • CDKN2A/p16 inactivation may not be a significant factor in the malignant transformation of ependymomas.